ABOUT US

ZHONGCHAO INC. (NasdaqCM: ZCMD)

Zhongchao Inc. a holding company incorporated under the laws of the Cayman Islands, through its variable interest entity and subsidiaries, provides healthcare information, education, and training services to healthcare professionals and the public in China. The Company commenced its operation, through Zhongchao Shanghai, in August 2012 with a vision to offer a wide range of accessible and immediate healthcare information and continuous learning and training opportunities for Chinese healthcare professionals.

More

Stock Chart
News
  • 01 Zhongchao Inc. Builds A Platform for Breast Cancer Tiered Diagnosis and Treatment Improvement To Promote the Equalization of Breast Cancer Diagnosis and Treatment Level

    SHANGHAI, July 27, 2021 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that for the first half of 2021, around 100,000 users had completed the learnings through the Breast Cancer Tiered Diagnosis and Treatment Improvement Platform ("Platform") built and operated by the Company.

  • 02 Zhongchao Inc. Launched New Line of Business Focusing on Tumor and Rare Disease Patient Management

    SHANGHAI, May 28, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin").

  • 03 Zhongchao Inc. Reports the Fiscal Year 2020 Financial Results

    Revenues and operating income grew 20.9% and 23.3%, respectively ​SHANGHAI, April 30, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced its financial results for the fiscal year ended December 31, 2020.

  • 04 Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline -Extending the Cooperation in Pulmonary Arterial Hypertension

    SHANGHAI, Mar. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program "Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals" (“PAH Project”) in 2021. The PAH Project aims to promote the implementation of the multidisciplinary treatment model of pulmonary hypertension and improve doctors ability to solve clinical problems. In 2020, more than 200 experts in pulmonary hypertension participated in the PAH Project, training a total of 10,000 clinicians. In 2021, we expect increased clinicians to participate in PHA Project to get training for knowledge updates, skill learning, and experience exchange in pulmonary hypertension. Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "Compared to the population base and the number of potential pulmonary hypertension patients in China, the number of physicians specializing in the diagnosis and treatment of this field is very limited. Therefore, our PAH project in 2020 had received positive response and recognition from the majority of clinicians. The success of the PAH project brings valuable experiences for us in educating rare diseases. We believe we will attract more social and commercial cooperation in promoting rare diseases education to grow our business further.”